Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 3/20 | 0.50 |
| ▸ | CCKBR | P32239 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | METAP1 | P53582 | 2/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29120118 | 0.90 | METAP2 (0.47) | METAP2HDAC1NR1H4NPC1RAB9A | |
| SCHEMBL21753951 | 0.90 | METAP2 (0.47) | METAP2HDAC1NR1H4NPC1RAB9A | |
| SCHEMBL9390095 | 0.86 | METAP2 (0.49) | METAP2HDAC1NR1H4NPC1RAB9A | |
| SCHEMBL6828289 | 0.83 | NAMPT (0.57) | METAP2NR1H4NPC1RAB9ATDP1 | |
| SCHEMBL10793524 | 0.82 | LTA4H (0.49) | METAP2HDAC1NR1H4NPC1RAB9A | |
| SCHEMBL985997 | 0.80 | LARS1 (0.58) | METAP2HDAC1NPC1RAB9AMETAP1 | |
| SCHEMBL8513563 | 0.80 | CCKBR (0.39) | METAP2CCKBRDHFRNR1H4PPARG | |
| SCHEMBL5321628 | 0.79 | DHFR (0.50) | HDAC1DHFRNPC1RAB9ATDP1 | |
| Hydrochloric Acid SCHEMBL8669233 | 0.79 | LARS1 (0.57) | METAP2HDAC1NPC1RAB9AMETAP1 | |
| SCHEMBL9115641 | 0.79 | MMP2 (0.41) | DHFRLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140045205-A1 | GLUTAMYL AMINOPEPTIDASE AS A MARKER OF RENAL DAMAGE | UNIVERSIDAD DE GRANADA (ES) | 2014-02-13 | — | — | US | claimed |
| EP-3937924-B1 | COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR TREATING HYPERTENSION OR HEART FAILURE | QUANTUM GENOMICS (FR) | 2023-09-06 | — | — | EP | disclosed |
| US-11345658-B2 | Compounds and compositions comprising the same for treating hypertension or heart failure | QUANTUM GENOMICS (FR) | 2022-05-31 | — | — | US | disclosed |
| US-11192907-B2 | Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same | QUANTUM GENOMICS (FR) | 2021-12-07 | — | — | US | disclosed |
| US-20210309678-A1 | AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Institut National de la Santé et de la Recherche Médicale (FR) | 2021-10-07 | — | — | US | disclosed |
| US-20210309677-A1 | NOVEL AMINOPHOSPHINIC DERIVATIVES AS AMINOPEPTIDASE A INHIBITORS | COLLEGE DE FRANCE (FR) | 2021-10-07 | — | — | US | disclosed |
| US-20140045205-A1 | GLUTAMYL AMINOPEPTIDASE AS A MARKER OF RENAL DAMAGE | UNIVERSIDAD DE GRANADA (ES) | 2014-02-13 | — | — | US | disclosed |
| US-8138311-B2 | Modified proteins, designer toxins, and methods of making thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110288275-A1 | Modified Proteins, Designer Toxins, and Methods of Making Thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2011-11-24 | — | — | US | disclosed |
| EP-1047413-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A SPECIFIC INHIBITOR OF AMINOPEPTIDASE A, IN PARTICULAR EC33, FOR DECREASING BLOOD PRESSURE | INST NAT SANTE RECH MED (FR) | 2011-08-03 | — | — | EP | disclosed |
| US-20020061840-A1 | Tripeptide compounds useful as selective inhibitors of aminopeptidase A and corresponding pharmaceutical compositions | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2002-05-23 | — | — | US | disclosed |
| US-6340708-B1 | DECREASING ARTERIAL PRESSURE | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-01-22 | — | — | US | disclosed |
| EP-1140981-A1 | TRIPEPTIDE COMPOUNDS USEFUL AS SELECTIVE INHIBITORS OF AMINOPEPTIDASE A AND CORRESPONDING PHARMACEUTICAL COMPOSITIONS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2001-10-10 | — | — | EP | disclosed |
| EP-1047413-A1 | PHARMAZEUTISCHE ZUSAMMENSTELLUNG | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2000-11-02 | — | — | EP | disclosed |
| WO-2000043414-A1 | TRIPEPTIDE COMPOUNDS USEFUL AS SELECTIVE INHIBITORS OF AMINOPEPTIDASE A AND CORRESPONDING PHARMACEUTICAL COMPOSITIONS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2000-07-27 | — | — | WO | disclosed |
| WO-1999036066-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE AMINOPEPTIDASE A INHIBITOR | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1999-07-22 | — | — | WO | disclosed |
| EP-0382990-A1 | Strains of bacillus thuringiensis | PLANT GENETIC SYSTEMS, N.V. (BE) | 1990-08-22 | — | — | EP | disclosed |
| US-4318847-A | ENZYME INHIBITORS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1982-03-09 | — | — | US | disclosed |
| US-4167448-A | AMASTATINS A1, A2, A3, B1 AND B2 PRODUCED BY AEROBIC CULTIVATION OF STREPTOMYCES | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1979-09-11 | — | — | US | disclosed |
| US-4126606-A | CONTAINING VALINE, AMASTATINS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1978-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192907-B2 | Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same | ANPEP, DNPEP, ENPEP | METAP2 25/4885CCKBR 3392/4885HDAC1 3108/4885 |
| US-20210309677-A1 | NOVEL AMINOPHOSPHINIC DERIVATIVES AS AMINOPEPTIDASE A INHIBITORS | ANPEP, DNPEP, ENPEP | METAP2 14/4885CCKBR 4143/4885HDAC1 3245/4885 |
| US-11345658-B2 | Compounds and compositions comprising the same for treating hypertension or heart failure | REN, APOB, PYGM | METAP2 1628/4885CCKBR 1975/4885HDAC1 2149/4885 |
| US-20210309678-A1 | AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ANPEP, DNPEP, ENPEP | METAP2 25/4885CCKBR 3392/4885HDAC1 3108/4885 |
| US-20020061840-A1 | Tripeptide compounds useful as selective inhibitors of aminopeptidase A and corresponding pharmaceutical compositions | ANPEP, DNPEP, ENPEP | METAP2 24/4885CCKBR 415/4885HDAC1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.